SynthesisNeurosurgical review2026
Flow diverting stents for anterior communicating artery aneurysms: A systematic review and meta-analysis of safety, efficacy, and anatomic determinants.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Flow diversion for anterior communicating artery (ACom) aneurysms remains technically challenging due to small vessel caliber, bifurcation anatomy, and perforator involvement. Although case series suggest feasibility, the overall efficacy and safety of flow-diverter (FD) treatment for ACom aneurysms are not well established. Purpose: To synthesize the available evidence on occlusion rates, complications, clinical outcomes, and retreatment following FD treatment for ACom aneurysms. Materials and methods: Following PRISMA guidelines, databases (PubMed/MEDLINE, Embase, Scopus, Web of Science, Cochrane Library) were searched for studies published January 2010–September 2025 including ≥ 3 patients treated with FD devices reporting angiographic or clinical outcomes. Extracted data encompassed study characteristics, demographics, aneurysm morphology, treatment details, occlusion, complications, and modified Rankin Scale (mRS). Pooled proportions with 95% confidence intervals (CIs) were calculated via random-effects model in R. Results: Twelve studies (297 patients; 304 ACom aneurysms) were included. Mean age was 64.6 ± 8.4 years; 50.4% were female. Aneurysms were mostly saccular (90.7%), unruptured (76.8%), and small (< 10 mm; mean 4.5 mm). PED was used in 43% of cases; adjunctive coiling in 17.6%. Pooled complete/near-complete occlusion (> 90%) was 78% (95% CI: 66%–86%) at mean 12.5-month follow-up. Pooled complication rate was 21% (95% CI: 13%–31%) and mortality 1% (95% CI: 0%–3%), with permanent morbidity ranged from 5 to 7% across reporting studies. Retreatment was 3.7%; good outcomes (mRS 0–2) 94.7%. Conclusion: FD may offer a technically feasible and potentially effective treatment option for select ACom aneurysms, with pooled data demonstrating 78% near-complete or complete occlusion and 94.7% good functional outcomes at 12.5 month follow-up. However, its role remains investigational, warranting prospective studies to better define long-term safety, durability, and optimal patient selection.
Indexed as
Identifiers
42047837What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.